Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
RXRX vs PVLA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PVLA Captures Overall Composite Edge (48.2 HOLD vs 49.5 HOLD), While RXRX Leads 5–1 on Growth & Valuation Pillars
PVLA Overall Winner
6-Pillar Tally: RXRX 5 – 1 PVLA
Matrix Metrics: RXRX 3 – 4 PVLA
As of Nov 16, 2026, Palvella Therapeutics, Inc. (PVLA) captures the overall head-to-head institutional edge over Recursion Pharmaceuticals, Inc. (RXRX) on higher Unified Composite conviction (48.2/100 HOLD vs. 49.5/100 HOLD) after splitting the core matrix 4–3 (led by Profitability & Quality), while RXRX wins 5–1 across the 6-pillar growth and valuation breakdown. RXRX trades at $2.90 (N/M Forward P/E, -734.2% operating margin) versus PVLA at $145.03 (N/M Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While RXRX currently prints a higher short-term Unified Composite Score (49.5/100 HOLD vs. PVLA 48.2/100 HOLD), PVLA captures the overall institutional head-to-head verdict (4–3 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -734.2% operating margin) and revenue trajectory (+0.0% vs. +258.5% YoY).
- Technical & Structure Timing Caution: RXRX is currently in a Breakdown options structure phase (RSI 35.7); meanwhile PVLA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About RXRX vs PVLA
RXRX
Recursion Pharmaceuticals, Inc. Class A Common Stock
$2.90
-8.79% 1D
Market Cap
$2.1B
TTM Revenue
$68M
Forward P/E
N/M
Beta / 30D Vol
3.01β · 85% Vol
Unified Composite Score
49.5
HOLD
Tech 40.0
Fund 56.0
Flow 69.0
Mom 64.0
Weinstein Technical Phase
Neutral · Hold
PVLA
Head-to-Head Winner
Palvella Therapeutics, Inc. Common Stock
$145.03
-4.89% 1D
Market Cap
$2.2B
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.66β · 75% Vol
Unified Composite Score
48.2
HOLD
Tech 35.0
Fund 53.0
Flow 67.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (RXRX 5 – 1 PVLA)
1. Valuation Multiples
RXRX
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
23.5x
N/M
2. Growth & Scale
RXRX
Revenue Growth (YoY)
+258.5%
+0.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$68M
N/A
Market Cap
$2.1B
$2.2B
3. Profitability & Quality
PVLA
Gross Margin
N/A
N/A
Operating Margin
-734.2%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-48.7%
-63.4%
4. Balance Sheet & Cash Flow
RXRX
Cash Generation (TTM)
-$314M
-$43M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$475M Net Cash
$193M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
RXRX
Options Structure Phase
BREAKDOWN
CONSOLIDATION
Current IV / %ile
92.3% (61st %ile)
47.9% (2nd %ile)
Put/Call OI Skew
0.58x (Call-Skewed)
3.82x (Put-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Neutral
DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat
RXRX
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: RXRX (3) vs PVLA (4)| Institutional Metric | RXRX | PVLA | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $2.1B | $2.2B | PVLA | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +258.5% | +0.0% | RXRX | |
| Operating Margin (TTM) | -734.2% | 0.0% | PVLA | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -48.7% | -63.4% | RXRX | |
| 52-Week Range Position | 6% ($3–$5) | 68% ($72–$180) | PVLA | |
| Beta / 30D Volatility | 3.01β · 85% Vol | 1.66β · 75% Vol | PVLA | |
| Unified Institutional Score | 49.5 / 100 (HOLD) | 48.2 / 100 (HOLD) | RXRX | |
| Trailing 12M Revenue (USD) | $68M | N/A | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 23.5x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$314M ($475M Net Cash) | -$43M ($193M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
PVLA +36.72 pp
3M Horizon
PVLA +2.41 pp
6M Horizon
PVLA +37.54 pp
1Y Horizon
PVLA +113.07 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | RXRX Revenue | PVLA Revenue | RXRX Op. Margin | PVLA Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $30M | N/A | -113.1% | PVLA |
| FY2019 | $0M | $40M | -2692.6% | -62.2% | PVLA |
| FY2020 | $0M | $30M | -2135.7% | -115.7% | PVLA |
| FY2021 | $10M | $30M | -1795.8% | -165.0% | PVLA |
| FY2022 | $40M | $30M | -616.7% | -167.8% | PVLA |
| FY2023 | $40M | $40M | -785.3% | -27.7% | PVLA |
| FY2024 | $60M | N/A | -814.1% | N/A | RXRX |
| FY2025 | $70M | N/A | -867.9% | N/A | RXRX |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
RXRX
BREAKDOWN
Current IV
92.3%
IV Percentile
61st %ile
Put/Call OI Skew
0.58x (Call-Skewed)
IV Regime
Elevated (60th–80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact RXRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
PVLA
CONSOLIDATION
Current IV
47.9%
IV Percentile
2nd %ile
Put/Call OI Skew
3.82x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact PVLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
RXRX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published · AI Drug Discovery
PVLA Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ RXRX vs PVLA Key Questions & Quantitative Answers
As of Nov 16, 2026, Palvella Therapeutics, Inc. (PVLA) captures the overall head-to-head institutional edge over Recursion Pharmaceuticals, Inc. (RXRX) on higher Unified Composite conviction (48.2/100 HOLD vs. 49.5/100 HOLD) after splitting the core matrix 4–3 (led by Profitability & Quality), while RXRX wins 5–1 across the 6-pillar growth and valuation breakdown. RXRX trades at $2.90 (N/M Forward P/E, -734.2% operating margin) versus PVLA at $145.03 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While RXRX currently prints a higher short-term Unified Composite Score (49.5/100 HOLD vs. PVLA 48.2/100 HOLD), PVLA captures the overall institutional head-to-head verdict (4–3 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -734.2% operating margin) and revenue trajectory (+0.0% vs. +258.5% YoY). Technical & Structure Timing Caution: RXRX is currently in a Breakdown options structure phase (RSI 35.7); meanwhile PVLA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
RXRX leads the Growth & Scale pillar: RXRX posts +258.5% YoY revenue growth and +0.0% YoY earnings growth on $68M TTM revenue (N/A gross margin, -734.2% operating margin), compared with PVLA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RXRX cumulative revenue shifted +600.0% while PVLA shifted +33.3%. In operating R&D and SG&A reinvestment, RXRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PVLA.
RXRX screens cheaper on headline valuation multiples. RXRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 23.5x EV/Revenue (unreported FCF margin), whereas PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RXRX (-48.7% ROE) versus PVLA (-63.4% ROE) capital efficiency.
In options market volatility and institutional positioning, RXRX carries 92.3% implied volatility (61st %ile, Elevated (60th–80th %ile)), a 0.58x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 85% Vol realized risk). By comparison, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
PVLA vs RXRX · Reverse Pair
RXRX vs TEM
· Sector Peer
RXRX vs SOUN
· Sector Peer
RXRX vs APLD
· Sector Peer
PVLA vs ORKA
· Sector Peer
PVLA vs DNTH
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem